<DOC>
	<DOC>NCT02810756</DOC>
	<brief_summary>The pharmacokinetics of a new formulation with Pazopanib will be studied. This will be done in a patient cohort of n = 12.</brief_summary>
	<brief_title>Study With Improved Solubility Pazopanib</brief_title>
	<detailed_description />
	<criteria>Locally advanced or metastatic cancer; Able and willing to give written consent; WHO performance status of 0, 1 or 2; Able and willing to undergo blood sampling for PK analysis; Minimal acceptable safety laboratory values; Negative pregnancy test for female patients with childbearing potential; Able and willing to swallow oral medication. Any treatment with investigational drugs within 30 days prior to receiving the investigational treatment; Any treatment with CYP3A4, BCRP or PGP interfering drugs; Patients who received treatment with Votrient(R) kess than 1 week ago; Woman who are pregnant or breast feeding; Patients suffering from any known condition that may influence the dissolution or absorption of Pazopanib.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>